Citations (92)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Sidhant Jain, Neha Vimal, Nilza Angmo, Madhumita Sengupta & Suraj Thangaraj. (2023) Dengue Vaccination: Towards a New Dawn of Curbing Dengue Infection. Immunological Investigations 52:8, pages 1096-1149.
Read now
Read now
Stephen J. Thomas & In-Kyu Yoon. (2019) A review of Dengvaxia®: development to deployment. Human Vaccines & Immunotherapeutics 15:10, pages 2295-2314.
Read now
Read now
Jian Hang Lam, Li Ching Ong & Sylvie Alonso. (2016) Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?. Expert Review of Vaccines 15:4, pages 483-495.
Read now
Read now
Kanakatte Raviprakash, Peifang Sun, Yossef Raviv, Thomas Luke, Nicholas Martin & Tadeusz Kochel. (2013) Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4′-aminomethyl-trioxsalen) is highly immunogenic in mice. Human Vaccines & Immunotherapeutics 9:11, pages 2336-2341.
Read now
Read now
Monica A McArthur, Marcelo B Sztein & Robert Edelman. (2013) Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Review of Vaccines 12:8, pages 933-953.
Read now
Read now
Kanakatte Raviprakash, Thomas Luke, John Doukas, Janine Danko, Kevin Porter, Timothy Burgess & Tadeusz Kochel. (2012) A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Human Vaccines & Immunotherapeutics 8:12, pages 1764-1768.
Read now
Read now
Robert Edelman. (2011) Unique challenges faced by the clinical evaluation of dengue vaccines. Expert Review of Vaccines 10:2, pages 133-136.
Read now
Read now
G William Letson, Pratap Singhasivanon, Eduardo Fernandez, Nihal Abeysinghe, Juan Jose Amador, Harold S Margolis & Robert Edelman. (2010) Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas. Human Vaccines 6:10, pages 802-809.
Read now
Read now
Sathyamangalam Swaminathan, Gaurav Batra & Navin Khanna. (2010) Dengue vaccines: state of the art. Expert Opinion on Therapeutic Patents 20:6, pages 819-835.
Read now
Read now
Maria G Guzman, Lisset Hermida, Lidice Bernardo, Rosa Ramirez & Gerardo Guillén. (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Review of Vaccines 9:2, pages 137-147.
Read now
Read now
Articles from other publishers (82)
Jessica Pintado Silva & Ana Fernandez-Sesma. (2023) Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. Journal of General Virology 104:3.
Crossref
Crossref
Scott B. Halstead & David W. Vaughn. 2023. Plotkin's Vaccines. Plotkin's Vaccines
275
285.e6
.
Scott B. Halstead. 2023. History of Arbovirology: Memories from the Field. History of Arbovirology: Memories from the Field
227
313
.
Stephen J. Thomas, Timothy P. Endy & Alan L. Rothman. 2020. Viral Infections of Humans. Viral Infections of Humans
1
65
.
Robert K. M. Choy, A. Louis Bourgeois, Christian F. Ockenhouse, Richard I. Walker, Rebecca L. Sheets & Jorge Flores. (2022) Controlled Human Infection Models To Accelerate Vaccine Development. Clinical Microbiology Reviews 35:3.
Crossref
Crossref
E. I. Kazachinskaia, D. V. Shanshin, D. N. Scherbakov & A. M. Shestopalov. (2022) Problematic questions in the development of specific prevention of dengue fever. Medical Immunology (Russia) 24:1, pages 19-30.
Crossref
Crossref
Jisang Park, Ju Kim & Yong-Suk Jang. (2022) Current status and perspectives on vaccine development against dengue virus infection. Journal of Microbiology 60:3, pages 247-254.
Crossref
Crossref
Michael K. McCracken, Caitlin H. Kuklis, Chandrika B. Kannadka, David A. Barvir, Mark A. Sanborn, Adam T. Waickman, Hayden C. Siegfried, Kaitlin A. Victor, Kristin L. Hatch, Rafael De La Barrera, Shannon D. Walls, Wiriya Rutvisuttinunt, Jeffrey R. Currier, Heather Friberg, Richard G. Jarman & Gregory D. Gromowski. (2021) Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques. npj Vaccines 6:1.
Crossref
Crossref
Josilene Ramos Pinheiro-Michelsen, Rayane da Silva Oliveira Souza, Itana Vivian Rocha Santana, Patrícia de Souza da Silva, Erick Carvalho Mendez, Wilson Barros Luiz & Jaime Henrique Amorim. (2020) Anti-dengue Vaccines: From Development to Clinical Trials. Frontiers in Immunology 11.
Crossref
Crossref
Megan Chesnut, Laura S. Muñoz, Georgina Harris, Dana Freeman, Lucio Gama, Carlos A. Pardo & David Pamies. (2019) In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment. Frontiers in Cellular and Infection Microbiology 9.
Crossref
Crossref
So-Chon Han, Nguyen-Xuan Huy & Mi-Young Kim. (2018) Enhanced expression of dengue virus EDIII-based tetravalent antigen protein using transgenic rice callus. Plant Biotechnology Reports 12:3, pages 207-215.
Crossref
Crossref
Clemente DiazLeyi LinLuis J. MartinezKenneth H. EckelsMaribel CamposRichard G. JarmanRafael De La BarreraEdith LepineJean-François Toussaint, Irma FeboBruce L. InnisStephen J. ThomasAlexander C. Schmidt. (2018) Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico. The American Journal of Tropical Medicine and Hygiene 98:5, pages 1435-1443.
Crossref
Crossref
Gregory D. Gromowski, Sandra Henein, Chandrika B. Kannadka, David A. Barvir, Stephen J. Thomas, Aravinda M. de Silva & Richard G. Jarman. (2018) Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine. Vaccine 36:18, pages 2403-2410.
Crossref
Crossref
Scott B. Halstead & Stephen J. Thomas. 2018. Plotkin's Vaccines. Plotkin's Vaccines
241
251.e6
.
Ee Leen Pang & Hwei-San Loh. (2017) Towards development of a universal dengue vaccine – How close are we?. Asian Pacific Journal of Tropical Medicine 10:3, pages 220-228.
Crossref
Crossref
Vincent Muturi-Kioi, David Lewis, Odile Launay, Geert Leroux-Roels, Alessandra Anemona, Pierre Loulergue, Caroline L. Bodinham, Annelies Aerssens, Nicola Groth, Allan Saul & Audino Podda. (2016) Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLOS ONE 11:8, pages e0157385.
Crossref
Crossref
Veerachai Watanaveeradej, Sriluck Simasathien, Mammen P. Mammen, Ananda Nisalak, Elodie Tournay, Phirangkul Kerdpanich, Rudiwilai Samakoses, Robert J. Putnak, Robert V. Gibbons, In-Kyu Yoon, Richard G. Jarman, Rafael De La Barrera, Philippe Moris, Kenneth H. Eckels, Stephen J. Thomas & Bruce L. Innis. (2016) Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children. The American Journal of Tropical Medicine and Hygiene 94:6, pages 1348-1358.
Crossref
Crossref
Niyati Khetarpal & Ira Khanna. (2016) Dengue Fever: Causes, Complications, and Vaccine Strategies. Journal of Immunology Research 2016, pages 1-14.
Crossref
Crossref
Gavin Screaton, Juthathip Mongkolsapaya, Sophie Yacoub & Catherine Roberts. (2015) New insights into the immunopathology and control of dengue virus infection. Nature Reviews Immunology 15:12, pages 745-759.
Crossref
Crossref
Kirsten S. Vannice, John T. Roehrig & Joachim Hombach. (2015) Next generation dengue vaccines: A review of the preclinical development pipeline. Vaccine 33:50, pages 7091-7099.
Crossref
Crossref
Stephen J. Thomas & Alan L. Rothman. (2015) Trials and Tribulations on the Path to Developing a Dengue Vaccine. American Journal of Preventive Medicine 49:6, pages S334-S344.
Crossref
Crossref
Stephen J. Thomas & Alan L. Rothman. (2015) Trials and tribulations on the path to developing a dengue vaccine. Vaccine 33, pages D24-D31.
Crossref
Crossref
Sarah L. George, Mimi A. Wong, Tina J. T. Dube, Karen L. Boroughs, Janae L. Stovall, Betty E. Luy, Aurelia A. Haller, Jorge E. Osorio, Linda M. Eggemeyer, Sharon Irby-Moore, Sharon E. Frey, Claire Y.-H. Huang & Dan T. Stinchcomb. (2015) Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. Journal of Infectious Diseases 212:7, pages 1032-1041.
Crossref
Crossref
A Ghosh & L Dar. (2015) Dengue vaccines: Challenges, development, current status and prospects. Indian Journal of Medical Microbiology 33:1, pages 3-15.
Crossref
Crossref
Jianchun Wei, Hui Chen & Jing An. (2014) Recent progress in dengue vaccine development. Virologica Sinica 29:6, pages 353-363.
Crossref
Crossref
Stephen J. Thomas. (2014) Developing a dengue vaccine: progress and future challenges. Annals of the New York Academy of Sciences 1323:1, pages 140-159.
Crossref
Crossref
Jorge E Osorio, Ivan D Velez, Cynthia Thomson, Liliana Lopez, Alejandra Jimenez, Aurelia A Haller, Shawn Silengo, Jaclyn Scott, Karen L Boroughs, Janae L Stovall, Betty E Luy, John Arguello, Mark E Beatty, Joseph Santangelo, Gilad S Gordon, Claire Y-H Huang & Dan T Stinchcomb. (2014) Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious Diseases 14:9, pages 830-838.
Crossref
Crossref
Elodie Tournay, Angkool Kerdpanich, Kenneth H. Eckels, Francis Dessy, Bruce L. Innis, Rafael De La Barrerra, Veerachai Watanaveeradej, Sriluck Simasathien, Jean-Fran?ois Toussaint, Richard G. Jarman, Robert V. Gibbons, Ananda Nisalak & Stephen J. Thomas. (2014) Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial. The American Journal of Tropical Medicine and Hygiene 91:1, pages 119-128.
Crossref
Crossref
C. M. Briggs, K. M. Smith, A. Piper, E. Huitt, C. J. Spears, M. Quiles, M. Ribeiro, M. E. Thomas, D. T. Brown & R. Hernandez. (2014) Live Attenuated Tetravalent Dengue Virus Host Range Vaccine Is Immunogenic in African Green Monkeys following a Single Vaccination. Journal of Virology 88:12, pages 6729-6742.
Crossref
Crossref
A. G. Lyons. (2014) The Human Dengue Challenge Experience at the Walter Reed Army Institute of Research. Journal of Infectious Diseases 209:suppl 2, pages S49-S55.
Crossref
Crossref
Eakachai Prompetchara, Chutitorn Ketloy, Poonsook Keelapang, Nopporn Sittisombut & Kiat Ruxrungtham. (2014) Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines. PLoS ONE 9:6, pages e92643.
Crossref
Crossref
U. THAVARA, A. TAWATSIN & Y. NAGAO. (2013) Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control. Epidemiology and Infection 142:6, pages 1245-1258.
Crossref
Crossref
Tomohiro Ishikawa, Atsushi Yamanaka & Eiji Konishi. (2014) A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32:12, pages 1326-1337.
Crossref
Crossref
Leyi Lin & Stephen J. Thomas. (2013) “Current Dengue Vaccine Status”. Current Tropical Medicine Reports 1:1, pages 6-12.
Crossref
Crossref
James Whitehorn & Jeremy FarrarMonica A McArthurMarcelo B SzteinRobert Edelman. 2014. Clinical Insights: Dengue: Transmission, Diagnosis & Surveillance. Clinical Insights: Dengue: Transmission, Diagnosis & Surveillance
103
119
.
Lauren E. Yauch & Sujan Shresta. 2014.
315
372
.
Stephen J. Thomas, Timothy P. Endy & Alan L. Rothman. 2014. Viral Infections of Humans. Viral Infections of Humans
351
381
.
Scott B. Halstead. (2013) Identifying protective dengue vaccines: Guide to mastering an empirical process. Vaccine 31:41, pages 4501-4507.
Crossref
Crossref
Roland Z?st, Hongping Dong, Xiao-Feng Li, David C. Chang, Bo Zhang, Thavamalar Balakrishnan, Ying-Xiu Toh, Tao Jiang, Shi-Hua Li, Yong-Qiang Deng, Brett R. Ellis, Esther M. Ellis, Michael Poidinger, Francesca Zolezzi, Cheng-Feng Qin, Pei-Yong Shi & Katja Fink. (2013) Rational Design of a Live Attenuated Dengue Vaccine: 2?-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques. PLoS Pathogens 9:8, pages e1003521.
Crossref
Crossref
Shannon Martin & Mary Hart. 2013. Viral Hemorrhagic Fevers. Viral Hemorrhagic Fevers
207
230
.
Kulkanya Chokephaibulkit & Guey Chuen Perng. (2013) Challenges for the formulation of a universal vaccine against dengue. Experimental Biology and Medicine 238:5, pages 566-578.
Crossref
Crossref
Adwoa D. Bentsi-Enchill, Julia Schmitz, Robert Edelman, Anna Durbin, John T. Roehrig, Peter G. Smith, Joachim Hombach & Jeremy Farrar. (2013) Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine 31:23, pages 2603-2609.
Crossref
Crossref
Ngoc-Luong Nguyen, Jung-Mi Kim, Jin-Ah Park, Seung-Moon Park, Yong-Suk Jang, Moon-Sik Yang & Dae-Hyuk Kim. (2013) Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae. Protein Expression and Purification 88:2, pages 235-242.
Crossref
Crossref
Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Daniel Elwood, Catherine J. Larsson, Janet C. Lindow, Cecilia Tibery, Beulah P. Sabundayo, Donna Shaffer, Kawsar R. Talaat, Noreen A. Hynes, Kimberli Wanionek, Marya P. Carmolli, Catherine J. Luke, Brian R. Murphy, Kanta Subbarao & Stephen S. Whitehead. (2013) A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial. The Journal of Infectious Diseases 207:6, pages 957-965.
Crossref
Crossref
W. Sun, K. H. Eckels, J. R. Putnak, A. G. Lyons, S. J. Thomas, D. W. Vaughn, R. V. Gibbons, S. Fernandez, V. J. Gunther, M. P. Mammen, J. D. Statler & B. L. Innis. (2012) Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines. Journal of Infectious Diseases 207:5, pages 700-708.
Crossref
Crossref
Lara J. Herrero, Andrew Zakhary, Michelle E. Gahan, Michelle A. Nelson, Belinda L. Herring, Andrew J. Hapel, Paul A. Keller, Maheshi Obeysekera, Weiqiang Chen, Kuo-Ching Sheng, Adam Taylor, Stefan Wolf, Jayaram Bettadapura, Shobha Broor, Lalit Dar & Suresh Mahalingam. (2013) Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesis. Pharmacology & Therapeutics 137:2, pages 266-282.
Crossref
Crossref
Stephen J. Thomas, Kenneth H. Eckels, Isabelle Carletti, Rafael De La Barrera, Francis Dessy, Stefan Fernandez, Robert Putnak, Jean-Francois Toussaint, Wellington Sun, Kristen Bauer, Robert V. Gibbons & Bruce L. Innis. (2013) A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults. The American Journal of Tropical Medicine and Hygiene 88:1, pages 73-88.
Crossref
Crossref
Rosmari Rodriguez-Roche & Ernest A. Gould. (2013) Understanding the Dengue Viruses and Progress towards Their Control. BioMed Research International 2013, pages 1-20.
Crossref
Crossref
Joshua M. Costin, Elena Zaitseva, Kristen M. Kahle, Cindo O. Nicholson, Dawne K. Rowe, Amanda S. Graham, Lindsey E. Bazzone, Greg Hogancamp, Marielys Figueroa Sierra, Rachel H. Fong, Sung-Tae Yang, Li Lin, James E. Robinson, Benjamin J. Doranz, Leonid V. Chernomordik, Scott F. Michael, John S. Schieffelin & Sharon Isern. (2013) Mechanistic Study of Broadly Neutralizing Human Monoclonal Antibodies against Dengue Virus That Target the Fusion Loop. Journal of Virology 87:1, pages 52-66.
Crossref
Crossref
Scott B. Halstead & Stephen J. Thomas. 2013. Vaccines. Vaccines
1042
1051
.
Sathyamangalam Swaminathan & Navin Khanna. 2013. Molecular Vaccines. Molecular Vaccines
135
151
.
Kaitlin Rainwater-Lovett, Isabel Rodriguez-Barraquer, Derek AT Cummings & Justin Lessler. (2012) Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infectious Diseases 12:1.
Crossref
Crossref
Carlos Casta?eda-Orjuela, Hernando D?az, Nelson Alvis-Guzman, Andres Olarte, Heidy Rodriguez, Guido Camargo & Fernando De la Hoz-Restrepo. (2012) Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011. Value in Health Regional Issues 1:2, pages 123-128.
Crossref
Crossref
C.A. Martínez, A.M. Giulietti & J. Rodríguez Talou. (2012) Research advances in plant-made flavivirus antigens. Biotechnology Advances 30:6, pages 1493-1505.
Crossref
Crossref
C. A. Laughlin, D. M. Morens, M. C. Cassetti, A. Costero-Saint Denis, J.-L. San Martin, S. S. Whitehead & A. S. Fauci. (2012) Dengue Research Opportunities in the Americas. Journal of Infectious Diseases 206:7, pages 1121-1127.
Crossref
Crossref
Lisset Hermida, Iris Valdés, Lázaro Gil, Lídice Bernardo, Laura Lazo, Yaremis Romero, María G. Guzmán & Gerardo Guillén. (2012) The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice. Archives of Virology 157:5, pages 987-991.
Crossref
Crossref
S. VONG, S. GOYET, S. LY, C. NGAN, R. HUY, V. DUONG, O. WICHMANN, G. W. LETSON, H. S. MARGOLIS & P. BUCHY. (2011) Under-recognition and reporting of dengue in Cambodia: a capture–recapture analysis of the National Dengue Surveillance System. Epidemiology and Infection 140:3, pages 491-499.
Crossref
Crossref
Eiji Konishi & Yuko Miyagawa. (2011) Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model. Microbes and Infection 13:12-13, pages 1091-1098.
Crossref
Crossref
Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Alexander C. Schmidt & Stephen S. Whitehead. (2011) Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:42, pages 7242-7250.
Crossref
Crossref
Beth-Ann G. Coller, David E. Clements, Andrew J. Bett, Sangeetha L. Sagar & Jan H. Ter Meulen. (2011) The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:42, pages 7267-7275.
Crossref
Crossref
Jorge E. Osorio, Claire Y.-H. Huang, Richard M. Kinney & Dan T. Stinchcomb. (2011) Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29:42, pages 7251-7260.
Crossref
Crossref
Julia Schmitz, John Roehrig, Alan Barrett & Joachim Hombach. (2011) Next generation dengue vaccines: A review of candidates in preclinical development. Vaccine 29:42, pages 7276-7284.
Crossref
Crossref
Anna P. Durbin, Stephen S. Whitehead, Donna Shaffer, Dan Elwood, Kimberli Wanionek, Bhavin Thumar, Joseph E. Blaney, Brian R. Murphy & Alexander C. Schmidt. (2011) A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial. PLoS Neglected Tropical Diseases 5:8, pages e1267.
Crossref
Crossref
Stephen J. Thomas, David W. Vaughn, Ananda Nisalak, Mammen P. Mammen, Veerachai Watanaveeradej, Sumetha Hengprasert, Angkool Kerdpanich, Kenneth H. Eckels, Sriluck Simasathien, Richard G. Jarman, Rudiwilai Samakoses, Rafael De La Barrera, Robert V. Gibbons, J. Robert Putnak, Timothy P. Endy & Bruce L. Innis. (2011) Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants. The American Journal of Tropical Medicine and Hygiene 85:2, pages 341-351.
Crossref
Crossref
K. B. Anderson, R. V. Gibbons, R. Edelman, K. H. Eckels, R. J. Putnak, B. L. Innis & W. Sun. (2011) Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate. Journal of Infectious Diseases 204:3, pages 442-450.
Crossref
Crossref
Alan L. Rothman. (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature Reviews Immunology 11:8, pages 532-543.
Crossref
Crossref
Muhammad Faheem, Ummar Raheel, Muhammad Nasir Riaz, Naghmana Kanwal, Farakh Javed, Najam us Sahar Sadaf Zaidi & Ishtiaq Qadri. (2010) A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies. Molecular Biology Reports 38:6, pages 3731-3740.
Crossref
Crossref
Beth-Ann G Coller & David E Clements. (2011) Dengue vaccines: progress and challenges. Current Opinion in Immunology 23:3, pages 391-398.
Crossref
Crossref
Ole Wichmann, In-Kyu Yoon, Sirenda Vong, Kriengsak Limkittikul, Robert V. Gibbons, Mammen P. Mammen, Sowath Ly, Philippe Buchy, Chukiat Sirivichayakul, Rome Buathong, Rekol Huy, G. William Letson & Arunee Sabchareon. (2011) Dengue in Thailand and Cambodia: An Assessment of the Degree of Underrecognized Disease Burden Based on Reported Cases. PLoS Neglected Tropical Diseases 5:3, pages e996.
Crossref
Crossref
S. J. Thomas. (2011) The Necessity and Quandaries of Dengue Vaccine Development. Journal of Infectious Diseases 203:3, pages 299-303.
Crossref
Crossref
Junu A. GeorgeSeong Kug Eo. (2011) Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2. Immune Network 11:5, pages 268.
Crossref
Crossref
Eiji Konishi. (2011) Issues Related to Recent Dengue Vaccine Development. Tropical Medicine and Health 39:4SUPPLEMENT, pages S63-S71.
Crossref
Crossref
Jorge Poo, Francisco Galan, Remi Forrat, Betzana Zambrano, Jean Lang & Gustavo H. Dayan. (2011) Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City. Pediatric Infectious Disease Journal 30:1, pages e9-e17.
Crossref
Crossref
Rekol HuyPhilippe BuchyAnne ConanChantha NganSivuth OngRabia AliVeasna DuongSunnara YitSophal UngVantha TeNorith ChroeungNguon Chan PheaktraVithiea UokSirenda Vong. (2010) National dengue surveillance in Cambodia 1980–2008: epidemiological and virological trends and the impact of vector control. Bulletin of the World Health Organization 88:9, pages 650-657.
Crossref
Crossref
Samantha Brandler, Claude Ruffie, Valérie Najburg, Marie-Pascale Frenkiel, Hughes Bedouelle, Philippe Desprès & Frédéric Tangy. (2010) Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28:41, pages 6730-6739.
Crossref
Crossref
Gaurav Batra, Rajendra Raut, Satinder Dahiya, Neha Kamran, Sathyamangalam Swaminathan & Navin Khanna. (2010) Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. Journal of Virological Methods 167:1, pages 10-16.
Crossref
Crossref
Sumana Chandramouli, Jeremiah S. Joseph, Sophie Daudenarde, Jovylyn Gatchalian, Cromwell Cornillez-Ty & Peter Kuhn. (2010) Serotype-Specific Structural Differences in the Protease-Cofactor Complexes of the Dengue Virus Family. Journal of Virology 84:6, pages 3059-3067.
Crossref
Crossref
Penelope Koraka, Byron E. E. Martina & Albert D. M. E. Osterhaus. (2010) Bioinformatics in New Generation Flavivirus Vaccines. Journal of Biomedicine and Biotechnology 2010, pages 1-17.
Crossref
Crossref
Monika Simmons, Timothy Burgess, Julia Lynch & Robert Putnak. (2010) Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396:2, pages 280-288.
Crossref
Crossref
Daniel P Webster, Jeremy Farrar & Sarah Rowland-Jones. (2009) Progress towards a dengue vaccine. The Lancet Infectious Diseases 9:11, pages 678-687.
Crossref
Crossref
Saima Khanam, Rajendra Pilankatta, Navin Khanna & Sathyamangalam Swaminathan. (2009) An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27:43, pages 6011-6021.
Crossref
Crossref
Xia Jin, Olivia Tono Block, Robert Rose & Jacob Schlesinger. (2008) Dengue vaccine development and dengue viral neutralization and enhancement assays. Antiviral Therapy 14:6, pages 739-749.
Crossref
Crossref